Economic impact in the management of dermatologic toxicities (dTs) induced by the epidermal growth factor receptor inhibitor (EGFRI) cetuximab in colorectal cancer.

3569 Background: Dermatologic toxicities including rash, xerosis, pruritus, paronychia, alopecia, mucositis and infections occur in up to 100% of colorectal cancer (CRC) patients treated with EGFRIs. These toxicities negatively affect quality of life but the associated financial impact has not been previously reported. This study evaluates the costs associated with management of cutaneous toxicities attributed to cetuximab in patients with CRC, who were referred to a dermatology-based program for the management of dTs in oncology, the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and Kinases) clinic. Methods: Medical records for a subset of 29 patients with CRC treated with cetuximab were indentified. Patient costs for dT related clinic visits, laboratory studies, diagnostic procedures, medications and supplies were assessed. Results: All patients (100%) presented with rash in addition to xerosis (72%), pruritus (38%), paronychia (34%) and alopecia (14%). A total of 29 patients had 99 clinic visits...